DailyIQ
|
Sector:Consumer DefensiveAll sectors
Last updated 4 minutes ago

KMB·Kimberly-Clark Corporation

$.
-. (-.%)
After Hours
High
$108.82
Open
$106.81
Market Cap
35.65B
52W High
$137.46
Low
$105.98
P. Close
$106.54
P/E
16.82
52W Low
$92.42
Fwd P/E
53.08
DailyIQ Est.
$116.52
Technical Score (1D)
41
SELL
News Sentiment
70
BULLISH
Kimberly‑Clark’s latest strategic pivot centers on science‑backed innovation, a move designed to accelerate sales growth by introducing new tissue and hygiene products that align with evolving consumer preferences. This shift is expected to lift the company’s market share and overall volume, potentially strengthening its competitive position in the personal‑care sector. By focusing on data‑driven product development, KMB aims to differentiate its offerings and capture higher‑margin segments. The immediate market implication is a potential uptick in revenue from the new product lines, which could offset any short‑term cost increases associated with research and development. Investors should watch the rollout schedule of these upcoming products, as timely launches will be critical to realizing the projected sales lift. The first quarter’s sales figures will serve as a barometer for the effectiveness of the innovation strategy, revealing whether the new products resonate with consumers. Additionally, monitoring consumer feedback and market share gains in key categories will help gauge the strategy’s broader impact. Finally, keep an eye on any regulatory or supply‑chain updates that could affect the availability of the new product portfolio.
Earnings Summary
Kimberly‑Clark Corporation is a consumer‑staples company that produces and distributes personal‑care products such as Huggies, Kleenex, and Kotex, operating through North America, International Personal Care, and International Family Care and Professional segments. In the most recent quarters, the firm reported EPS of $1.93 in Q1 2025 and $1.92 in Q2 2025, both beating estimates of $1.89138 and $1.65553 respectively, while revenue declined from $4.840 billion to $4.163 billion, a reversal of the prior quarter’s $4.170 billion growth; the Q3 2025 EPS of $1.82 beat the $1.75111 estimate and Q4 2025 EPS of $1.86 surpassed the $1.8291 forecast, but Q4 2024 EPS of $1.50 missed the $1.51425 estimate and Q1 2026 EPS of $1.97 fell short of the $2.07087 projection. Historically, Kimberly‑Clark has delivered EPS beats in four of the last six quarters, with revenue growth generally positive but showing a slight dip in Q3‑Q4 2025 before rebounding in Q1 2026, reflecting the company’s stable demand base. Recent news highlights the firm’s low‑debt, balance‑sheet‑heavy posture and its announced integration of Kenvue’s consumer‑health portfolio in the second half of 2026, which could broaden its product mix and geographic reach; analysts note that any cost‑synergy claims or integration challenges will be closely watched. Investors should watch for the Q2 2026 earnings release, where guidance on cash‑flow generation, debt‑management plans, and the progress of the Kenvue integration will be key, as macro consumer‑spending trends and interest‑rate movements could influence the company’s earnings stability. The company’s dividend policy remains a key attraction for income‑focused investors.

EPS

EstBeatMiss
$1.59$1.73$1.86$2.00$2.13Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$2.01 - -
Q1'26$2.07$1.97-4.9%
Q4'25$1.83$1.86+1.7%
Q3'25$1.75$1.82+3.9%
Q2'25$1.66$1.92+16.0%
Q1'25$1.89$1.93+2.0%

Revenue

EstBeatMiss
$4.0B$4.2B$4.5B$4.7B$5.0BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$4.3B - -
Q1'26$4.3B$4.2B-2.1%
Q4'25$4.1B$4.1B-1.2%
Q3'25 - $4.2B -
Q2'25 - $4.2B -
Q1'25 - $4.8B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

KMB Stock Snapshot

KMB is currently trading at $106.53, giving Kimberly-Clark Corporation a market cap of 35.65B and a P/E ratio of 16.8. Today's range spans $105.98–$108.82, with shares opening at $106.81 and moving down $0.01 (0.0%) from the prior close. DailyIQ's technical score sits at 41/100 (HOLD) with a news sentiment reading of 70/100.

Over the past year KMB has traded between $92.42 and $137.46 - the current price is +15.3% off the 52-week low and -22.5% from the high. 22 analysts cover the stock with a Hold consensus and a mean 12-month target of $115.47 (range $90.00–$162.00), implying upside of +8.4%.

The quality factor scores well for Kimberly-Clark Corporation (KMB) even in a HOLD phase - at 35.65B in Consumer Defensive market cap with a 41/100 technical read (HOLD) and bullish sentiment (70/100), the stock's balance sheet and earnings stability attract defensive allocators who don't need a mixed signal to hold the position. (P/E: 16.8) Price: $106.53 (in the lower half of its 52-week range). Range: $92.42–$137.46.

The 52-week range of $92.42–$137.46 for KMB provides the structural reference that options traders, systematic funds, and discretionary managers all anchor to — and at $106.53 (in the lower half of its 52-week range), the stock sits in a zone where the next 5–10% move will likely define which crowd was right. A HOLD signal at 41/100 and bullish news backdrop (70/100) don't break the tie yet, but they narrow the probability distribution toward the upside.